stoxline Quote Chart Rank Option Currency Glossary
Palisade Bio, Inc. (PALI)
0.611  -0.037 (-5.71%)    12-07 15:57
Open: 0.63
High: 0.642
Volume: 51,221
Pre. Close: 0.648
Low: 0.611
Market Cap: 6(M)
Technical analysis
2023-12-07 4:22:37 PM
Short term     
Mid term     
Targets 6-month :  0.81 1-year :  0.95
Resists First :  0.69 Second :  0.81
Pivot price 0.6
Supports First :  0.57 Second :  0.5
MAs MA(5) :  0.63 MA(20) :  0.58
MA(100) :  0.83 MA(250) :  1.56
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  62.1 D(3) :  67.6
RSI RSI(14): 54
52-week High :  8.53 Low :  0.5
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ PALI ] has closed below upper band by 35.8%. Bollinger Bands are 78.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 50 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.64 - 0.65 0.65 - 0.65
Low: 0.6 - 0.61 0.61 - 0.61
Close: 0.62 - 0.62 0.62 - 0.63
Company Description

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.

Headline News

Fri, 10 Nov 2023
Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook - GlobeNewswire

Wed, 11 Oct 2023
Palisade Bio to Participate at the Virtual Investor Ask the CEO Conference - Yahoo Finance

Thu, 14 Sep 2023
Insider Buying: John Finley Acquires 15,000 Shares of Palisade Bio Inc - Yahoo Finance

Mon, 11 Sep 2023
What's Happening With Palisade Bio Stock? - Palisade Bio (NASDAQ:PALI) - Benzinga

Thu, 07 Sep 2023
Palisade Bio Announces $2 Million Registered Direct Offering of Common Stock Priced At Market Under Nasdaq Rules - GlobeNewswire

Thu, 07 Sep 2023
Why Is Palisade Bio (PALI) Stock Down 46% Today? - InvestorPlace

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 9 (M)
Held by Insiders 9.08e+006 (%)
Held by Institutions 1.7 (%)
Shares Short 215 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.34e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -5 %
Return on Assets (ttm) 360.7 %
Return on Equity (ttm) -50.3 %
Qtrly Rev. Growth 250000 %
Gross Profit (p.s.) 0
Sales Per Share -70.32
EBITDA (p.s.) 0
Qtrly Earnings Growth 0.3 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -12 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.56
Stock Dividends
Dividend 0
Forward Dividend 66630
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android